Radioactive iodine (RAI) treatment is an effective treatment for differentiated thyroid cancer (DTC); however, many patients are refractory. Using targeted drugs to reinduce RAI sensitivity (“redifferentiation therapy”) has long been sought after as the holy grail in endocrine oncology.

See related article by Weber et al., p. 4194

©2022 American Association for Cancer Research
2022
American Association for Cancer Research
You do not currently have access to this content.